===========================================================================
                  AVEUM SYSTEMS CORPORATION
             MUTUAL NON-DISCLOSURE AGREEMENT (NDA)
===========================================================================

This Non-Disclosure Agreement (the "Agreement") is effective as of 
February 18, 2026.

PARTIES:
Disclosing Party: AVEUM SYSTEMS CORPORATION & AVEUM GENETIC RESEARCH FOUNDATION
Receiving Party: [INSERT LEGAL ENTITY NAME BELOW]

1. DEFINITION OF CONFIDENTIAL INFORMATION
Confidential Information includes all genomic research, the "Global Human 
Identification" patent-pending methodology, SNP primary key selection logic, 
mitochondrial confirmation protocols, and any technical data transmitted 
via the Aveum Ingestion Bridge.

2. NON-USE AND NON-DISCLOSURE
The Receiving Party shall maintain the Confidential Information in strict 
confidence and shall not disclose it to any third party or use it for any 
purpose outside of the specific REASON TO EVALUATE THE SOFTWARE with Aveum 
Systems FOR LICENSING.

3. REVERSE ENGINEERING PROHIBITION
The Receiving Party is strictly prohibited from attempting to reverse-engineer 
the Genomic Duplicate Safety Hash or any underlying algorithms used in the 
Aveum identification system and by attempting to do so acknowledges that Aveum 
Systems will pursue the Receiving Party in enforce damages which may be deemed
very significant by the Court. 


4. US PATENT PENDING STATUS By receiving information from Aveum on its GIS 
Technology, Receiver understands that the complete process is subject to a Patent
Pending Status Rules and Regulations governing disclosure. 

5. OWNERSHIP
Disclosing Party retains all rights, title, and interest in and to the 
Confidential Information and all Intellectual Property Rights therein.

6. The Parties agree to be bound by the Laws of the State of Delaware, USA
in respect to all use and testing of this software by the Receiver under 
this NDA and both Parties agree to Delaware, (exclusively) as the LEGAL 
AND BINDING jurisdiction should any dispute arise between the Disclosing 
Party and Receiving Party.

---------------------------------------------------------------------------
IN WITNESS WHEREOF, the parties have executed this Agreement by their 
duly authorized representatives.

DISCLOSING PARTY:
Aveum Systems Corporation / Aveum Genetic Research Foundation

Name: Scott Spears
Title: Director 


RECEIVING PARTY:

Entity Name: ______________________________________________________________

Authorized Signature: ______________________________________________________

Printed Name: _____________________________________________________________

Title: ____________________________________________________________________

Date: __________________________
---------------------------------------------------------------------------